[go: up one dir, main page]

CO5700785A2 - Composiciones inmunogenicas novedosas para la prevencion y el tratamiento de enfermedad meningococal - Google Patents

Composiciones inmunogenicas novedosas para la prevencion y el tratamiento de enfermedad meningococal

Info

Publication number
CO5700785A2
CO5700785A2 CO05116231A CO05116231A CO5700785A2 CO 5700785 A2 CO5700785 A2 CO 5700785A2 CO 05116231 A CO05116231 A CO 05116231A CO 05116231 A CO05116231 A CO 05116231A CO 5700785 A2 CO5700785 A2 CO 5700785A2
Authority
CO
Colombia
Prior art keywords
meningococal
disease
prevention
treatment
immunogenic compositions
Prior art date
Application number
CO05116231A
Other languages
English (en)
Inventor
Gary W Zlotnick
Leah D Fletcher
John Farley
Liesel Bernfield
Robert J Zagursky
Benajmin J Metcalf
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CO5700785A2 publication Critical patent/CO5700785A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

1.- Una composición que comprende:(a) por lo menos una proteína que comprende la secuencia de aminoácido de cualquiera de las ID DE SEC NOS: 444-452;(b) por lo menos una proteína que comprende una secuencia de aminoácido que es codificada por un nucleótido que hibridiza bajo condiciones de restricción a cualquiera de los polinucleótidos que codifican cualquiera de las ID DE SEC NOS: 444-452;(c) por lo menos una porción inmunogénica de por lo menos una proteína descrita en (a) o (b); opor lo menos un equivalente biológico de por lo menos una proteína descrita en (a) o (b) o porción inmunogénica descrita en (c).
CO05116231A 2003-04-16 2005-11-16 Composiciones inmunogenicas novedosas para la prevencion y el tratamiento de enfermedad meningococal CO5700785A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46316103P 2003-04-16 2003-04-16

Publications (1)

Publication Number Publication Date
CO5700785A2 true CO5700785A2 (es) 2006-11-30

Family

ID=33310752

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05116231A CO5700785A2 (es) 2003-04-16 2005-11-16 Composiciones inmunogenicas novedosas para la prevencion y el tratamiento de enfermedad meningococal

Country Status (11)

Country Link
US (5) US20070253964A1 (es)
EP (1) EP1618185A4 (es)
JP (1) JP2006525330A (es)
KR (1) KR20060019515A (es)
CN (1) CN1867354A (es)
AU (2) AU2004233012A1 (es)
BR (1) BRPI0409459A (es)
CA (1) CA2522751A1 (es)
CO (1) CO5700785A2 (es)
MX (1) MXPA05011110A (es)
WO (1) WO2004094596A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69937419T2 (de) 1998-05-01 2008-07-24 Novartis Vaccines and Diagnostics, Inc., Emeryville Neisseria Meningitidis Antigene und Zusammenstellungen
EP2270174A1 (en) 1999-05-19 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Combination neisserial compositions
PT2275554E (pt) 1999-10-29 2015-06-26 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
PT1790660E (pt) 2000-02-28 2012-09-17 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN113198012B (zh) 2005-04-08 2024-09-17 惠氏有限责任公司 多价肺炎球菌多糖－蛋白质缀合物组合物
WO2007042326A2 (en) * 2005-10-14 2007-04-19 Intercell Ag Neisseria meningitidis antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
SI2061897T1 (sl) 2006-07-27 2020-07-31 Wyeth Llc Postopek fermentacije s tehniko dohranjevalne šarže za celice z visoko gostoto za proizvajanje rekombinantnega proteina
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
ES2532946T3 (es) 2008-02-21 2015-04-06 Novartis Ag Polipéptidos PUfH meningocócicos
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
SMT202000366T1 (it) 2009-03-24 2020-09-10 Glaxosmithkline Biologicals Sa Proteina legante fattore h di meningococco come adiuvante
CN104650241A (zh) 2009-08-27 2015-05-27 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
CN102917730A (zh) * 2009-10-27 2013-02-06 诺华有限公司 修饰的脑膜炎球菌fHBP多肽
WO2011110634A1 (en) * 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Vaccine composition
CN107641151B (zh) * 2010-05-14 2021-10-01 百深公司 Ospa嵌合体及其在疫苗中的用途
RU2607024C2 (ru) 2010-06-04 2017-01-10 УАЙТ ЭлЭлСи Вакцины streptococcus pneumoniae
CA2803239A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
PL3246044T5 (pl) * 2010-08-23 2024-06-17 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
PE20140173A1 (es) * 2010-09-10 2014-02-20 Wyeth Llc Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
US10596246B2 (en) 2011-12-29 2020-03-24 Glaxosmithkline Biological Sa Adjuvanted combinations of meningococcal factor H binding proteins
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP4043029A1 (en) 2012-03-09 2022-08-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10376573B2 (en) 2012-06-14 2019-08-13 Glaxosmithkline Biologicals Sa Vaccines for serogroup X meningococcus
AU2013295242C1 (en) 2012-07-27 2018-08-09 Institut National De La Sante Et De La Recherche Medicale CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
EP3041502A2 (en) 2013-09-08 2016-07-13 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EA034954B1 (ru) 2014-02-28 2020-04-10 Глаксосмитклайн Байолоджикалс Са МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
US10888611B2 (en) * 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
JP7010961B2 (ja) 2017-01-31 2022-02-10 ファイザー・インク 髄膜炎菌組成物およびその方法
KR102871663B1 (ko) 2019-09-27 2025-10-16 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법
GB202016604D0 (en) * 2020-10-20 2020-12-02 Univ Of Oxford Compositions and methods for inducing an immune response
CN113372571A (zh) * 2021-07-05 2021-09-10 云南紫辰集团生物科技有限公司 黄腐酸钾干粉的生产工艺
CN114295845B (zh) * 2021-12-01 2024-07-19 柏荣诊断产品（上海）有限公司 一种高特异性透散射一体法降钙素原胶乳比浊检测试剂盒

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US466829A (en) * 1892-01-12 Carpet-stretcher
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4861719A (en) * 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4980289A (en) * 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5124263A (en) * 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
JPH07502646A (ja) * 1991-10-21 1995-03-23 メディミューン，インコーポレーテッド リポタンパク質の分泌シグナルをコード化するｄｎａを含む細菌発現ベクター
FR2708622B1 (fr) * 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
DE19723095C2 (de) * 1997-06-02 2001-08-23 Siemens Ag Bildrekonstruktionsverfahren für einen Computertomographen
AU2313199A (en) * 1998-02-03 1999-08-23 Center For Disease Control And Prevention Recombinant lipidated psaa protein, methods of preparation and use
DE69937419T2 (de) * 1998-05-01 2008-07-24 Novartis Vaccines and Diagnostics, Inc., Emeryville Neisseria Meningitidis Antigene und Zusammenstellungen
DK1117435T3 (da) * 1998-09-30 2008-03-17 Wyeth Corp Muteret cholera-holotoxin som adjuvans
WO2003025132A2 (en) * 2001-09-14 2003-03-27 Invitrogen Corporation Dna polymerases and mutants thereof
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741

Also Published As

Publication number Publication date
CN1867354A (zh) 2006-11-22
AU2004233012A1 (en) 2004-11-04
KR20060019515A (ko) 2006-03-03
US20070082007A1 (en) 2007-04-12
JP2006525330A (ja) 2006-11-09
US20070082006A1 (en) 2007-04-12
AU2010200892A1 (en) 2010-04-01
EP1618185A4 (en) 2009-05-27
EP1618185A2 (en) 2006-01-25
WO2004094596A8 (en) 2006-06-15
US20070253964A1 (en) 2007-11-01
US20090202593A1 (en) 2009-08-13
WO2004094596A2 (en) 2004-11-04
BRPI0409459A (pt) 2006-05-02
US20070082866A1 (en) 2007-04-12
CA2522751A1 (en) 2004-11-04
MXPA05011110A (es) 2006-01-24

Similar Documents

Publication Publication Date Title
CO5700785A2 (es) Composiciones inmunogenicas novedosas para la prevencion y el tratamiento de enfermedad meningococal
CO5700788A2 (es) Composiciones y metodos para inmunoterapia especifica de wt1
AR049014A1 (es) Mimeticuerpos de glp-1 humanos , composiciones y usos
PE27897A1 (es) Variantes bpn` que tienen absorbion disminuida e hidrolisis aumentada, en donde se sustituye una o mas regiones de enlace
AR050095A1 (es) Secuencias de subinidades pequenas de sintasa acetohidroxiacida de monocotiledoneas y metodos de uso.
PT1548032E (pt) Péptidos kdr e vacinas que os contêm
ATE446313T1 (de) Muteine von tränen-lipocalin
BR9814276A (pt) Antìgenos de superfìcie
ECSP056189A (es) Composiciones y método para el tratamiento de infecciones en ganado vacuno y porcino
GT199800083A (es) Agonistas de prostaglandinas.
MX2010002018A (es) Peptido de cdh3 y agente medicinal que comprende al mismo.
BRPI0412991A (pt) composição, lenço, e, métodos de utilização da composição e do lenço e de tratamento de um substrato
ECSP024244A (es) Uso de (z)-2-cyano-3-hydroxy-but-2-enoic acid(4´-trifluoromethylphenyl)-amide para el tratamiento de la esclerosis múltiple
ECSP066495A (es) Composiciones y metodos para inhibir la infección por virus de síndrome de punto blanco (wssv)
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
CO5590933A2 (es) Composicion y metodo para el tratamiento de la diabetes
BR0315836A (pt) Derivados de [6,7-dihidro-5h-imidazol[1,2-alfa]imadazol-3-sulfonila mino]-propionamida, composição farmacêutica, uso do mesmo, bem como processo para sua preparação
WO2006095347A3 (en) VOLTAGE DEPENDENT ANION CHANNEL (VDACl) COMPOSITIONS AND METHODS OF USE THEREOF FOR REGULATING APOPTOSIS
PT640098E (pt) Gene de coronavirus canino e suas utilizacoesc
AR045000A1 (es) Gen y proteina de eimeria , y su uso
PE20061441A1 (es) Genes y proteinas novedosos de brachyspira hyodysenteriae y uso de los mismos para diagnostico y terapia
BRPI0413437A (pt) preparação de peptìdeos de somatostatina
BRPI0412477A (pt) aperfeiçoados polipeptìdeos de interferon-beta-1b recombinantes humanos
DE60235505D1 (de) Neues verfahren und neue zusammensetzung zur hemmurwendung von verbindungen auf basis einer sequenz in mmp-2
DE60224280D1 (de) Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis

Legal Events

Date Code Title Description
FC Application refused